Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03438032 · ClinicalTrials.gov registry record
Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD
A clinical trial of Systemic Sclerosis and Fibrosis Lung, sponsored by Northwestern University.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT03438032 is a study of Systemic Sclerosis and Fibrosis Lung that has completed, run by Northwestern University. The registered enrollment target is 10 participants, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03438032, a study of Systemic Sclerosis and Fibrosis Lung, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveolar macrophage population, using single cell RNA-Seq technology to measure the individual transcriptome from each cell.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Bronchoscopy with lavage
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-28 |
| Est. Completion | 2024-03-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03438032
The ClinicalTrials.gov registry entry for NCT03438032 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 279-participant average among 26 other Systemic Sclerosis trials with a reported enrollment target (96% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Systemic Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Bronchoscopy with lavage is the first listed.
NCT03438032 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03438032 about?
NCT03438032 is a clinical study titled "Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD". Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveo...
What is the current status of trial NCT03438032?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2018-06-28. Estimated completion is 2024-03-08.
What conditions does trial NCT03438032 study?
This clinical trial studies the following conditions: Systemic Sclerosis, Fibrosis Lung.
What interventions are being tested in trial NCT03438032?
The interventions under investigation include: Bronchoscopy with lavage (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03438032?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03438032 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
New Orleans Pulmonary Hypertension Biobank
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.